Suppr超能文献

利用亲脂性盐使亲脂性药物在基于脂质的制剂中实现高载药量:亲脂性反离子的探索及体内外评价。

Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation.

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Punjab, India.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Punjab, India.

出版信息

Int J Pharm. 2024 May 10;656:124108. doi: 10.1016/j.ijpharm.2024.124108. Epub 2024 Apr 9.

Abstract

Lipid-based formulations (LbFs) are an extensively used approach for oral delivery of poorly soluble drug compounds in the form of lipid suspension and lipid solution. However, the high target dose and inadequate lipid solubility limit the potential of brick dust molecules to be formulated as LbFs. Thus, the complexation of such molecules with a lipophilic counterion can be a plausible approach to improve the solubility in lipid-based solutions via reducing drug crystallinity and polar surface area. The study aimed to enhance drug loading in lipid solution for Nilotinib (Nil) through complexation or salt formation with different lipophilic counterions. We synthesized different lipophilic salts/ complexes via metathesis reactions and confirmed their formation by H NMR and FTIR. Docusate-based lipophilic salt showed improved solubility in medium-chain triglycerides (∼7 to 7.5-fold) and long-chain triglycerides (∼30 to 35-fold) based lipids compared to unformulated crystalline Nil. The increased lipid solubility could be attributed to the reduction in drug crystallinity which was further confirmed by the PXRD and DSC. Prototype LbFs were prepared to evaluate drug loading and their physicochemical characteristics. The findings suggested that structural features of counterion including chain length and lipophilicity affect the drug loading in LbF. In addition, physical stability testing of formulations was performed, inferring that aliphatic sulfate-based LbFs were stable with no sign of drug precipitation or salt disproportionation. An in vitro lipolysis-permeation study revealed that the primary driver of absorptive flux is the solubilization of the drug and reduced amount of lipid. Further, the in vivo characterization was conducted to measure the influence of increased drug load on oral bioavailability. Overall, the results revealed enhanced absorption of lipophilic salt-based LbF over unformulated crystalline Nil and conventional LbF (drug load equivalent to equilibrium solubility) which supports the idea that lipophilic salt-based LbF enhances drug loading, and supersaturation-mediated drug solubilization, unlocking the full potential of LbF.

摘要

脂质体制剂(LbF)是一种广泛用于将疏水性药物化合物制成脂质混悬液和脂质溶液形式进行口服递送的方法。然而,高靶剂量和不足的脂溶性限制了将砖尘分子制成 LbF 的潜力。因此,通过降低药物结晶度和极性表面积,将此类分子与亲脂性反离子复合可以是提高脂质基溶液中溶解度的合理方法。本研究旨在通过与不同亲脂性反离子复合或形成盐来提高尼洛替尼(Nil)在脂质溶液中的药物载药量。我们通过复分解反应合成了不同的亲脂性盐/复合物,并通过 1H NMR 和 FTIR 确认了它们的形成。与未成型的结晶 Nil 相比,基于十二酸酯的亲脂性盐在中链甘油三酯(约 7 至 7.5 倍)和长链甘油三酯(约 30 至 35 倍)中的溶解度提高。脂溶性的提高可归因于药物结晶度的降低,这进一步通过 PXRD 和 DSC 得到证实。制备了原型 LbF 以评估药物载药量及其理化性质。研究结果表明,反离子的结构特征,包括链长和疏水性,影响 LbF 中的药物载药量。此外,还进行了制剂物理稳定性测试,推断基于脂肪硫酸盐的 LbF 是稳定的,没有药物沉淀或盐歧化的迹象。体外脂肪酶-渗透研究表明,吸收通量的主要驱动力是药物的增溶和减少的脂质量。此外,还进行了体内特征研究,以测量增加药物载药量对口服生物利用度的影响。总的来说,结果表明,亲脂性盐基 LbF 的吸收优于未成型的结晶 Nil 和常规 LbF(药物载药量相当于平衡溶解度),这支持了亲脂性盐基 LbF 可以提高药物载药量和超饱和介导的药物增溶,从而释放 LbF 的全部潜力的观点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验